496 related articles for article (PubMed ID: 8989246)
1. A low starting dose of genotropin in growth hormone-deficient adults.
Janssen YJ; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1997 Jan; 82(1):129-35. PubMed ID: 8989246
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3.
Juul A; Kastrup KW; Pedersen SA; Skakkebaek NE
J Clin Endocrinol Metab; 1997 Apr; 82(4):1195-201. PubMed ID: 9100596
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.
de Boer H; Blok GJ; Popp-Snijders C; Stuurman L; Baxter RC; van der Veen E
J Clin Endocrinol Metab; 1996 Apr; 81(4):1371-7. PubMed ID: 8636336
[TBL] [Abstract][Full Text] [Related]
4. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
[TBL] [Abstract][Full Text] [Related]
6. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
Bengtsson BA; Abs R; Bennmarker H; Monson JP; Feldt-Rasmussen U; Hernberg-Stahl E; Westberg B; Wilton P; Wüster C
J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
[TBL] [Abstract][Full Text] [Related]
7. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life.
Aguiar-Oliveira MH; Gill MS; de A Barretto ES; Alcântara MR; Miraki-Moud F; Menezes CA; Souza AH; Martinelli CE; Pereira FA; Salvatori R; Levine MA; Shalet SM; Camacho-Hubner C; Clayton PE
J Clin Endocrinol Metab; 1999 Nov; 84(11):4118-26. PubMed ID: 10566659
[TBL] [Abstract][Full Text] [Related]
8. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
[TBL] [Abstract][Full Text] [Related]
9. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency.
Juul A; Holm K; Kastrup KW; Pedersen SA; Michaelsen KF; Scheike T; Rasmussen S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1997 Aug; 82(8):2497-502. PubMed ID: 9253324
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
12. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
[TBL] [Abstract][Full Text] [Related]
13. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults.
Maghnie M; Strigazzi C; Tinelli C; Autelli M; Cisternino M; Loche S; Severi F
J Clin Endocrinol Metab; 1999 Apr; 84(4):1324-8. PubMed ID: 10199773
[TBL] [Abstract][Full Text] [Related]
15. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
[TBL] [Abstract][Full Text] [Related]
16. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
Gill MS; Toogood AA; Jones J; Clayton PE; Shalet SM
J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
[TBL] [Abstract][Full Text] [Related]
17. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
[TBL] [Abstract][Full Text] [Related]
18. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.
Tillmann V; Patel L; Gill MS; Whatmore AJ; Price DA; Kibirige MS; Wales JK; Clayton PE
Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the components of the insulin-like growth factors system in GH-deficient adults: effects of twelve-month rhGH treatment.
Ferrante E; Giavoli C; Porretti S; Vassallo E; Ronchi CL; Lania AG; Beck-Peccoz P; Spada A
Horm Metab Res; 2006 May; 38(5):352-5. PubMed ID: 16718634
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects.
Hilding A; Hall K; Wivall-Helleryd IL; Sääf M; Melin AL; Thorén M
J Clin Endocrinol Metab; 1999 Jun; 84(6):2013-9. PubMed ID: 10372703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
